Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its fourth quarter and full year 2022 financial results on March 9, 2023, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET. The company focuses on treatments for genetically defined rare diseases, with two lead clinical programs: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease. For more details, access the conference call via telephone or the company's website.

Positive

• Preparation for the fourth quarter 2022 earnings call indicates ongoing engagement with investors.
• Focus on rare diseases aligns with high unmet medical needs, suggesting potential for market growth.

Negative

• No specific financial data released in the PR may lead to uncertainty among investors until earnings call.

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2022 financial results will be released on Thursday, March 9, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Individuals may participate in the live call via telephone by dialing (877) 407-0792 (domestic) or (201) 689-8263 (international) and using the conference ID: 13735955 or by clicking on this link and requesting a return call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter @FulcrumTx and LinkedIn.

Contact:

Investors:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608

Media:
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324

FAQ

When will Fulcrum Therapeutics release its fourth quarter and full year 2022 financial results?

Fulcrum Therapeutics will release its financial results on March 9, 2023.

What time is the earnings call for Fulcrum Therapeutics?

The earnings call will take place at 8:00 a.m. ET on March 9, 2023.

How can I access the Fulcrum Therapeutics earnings call?

You can participate by dialing (877) 407-0792 for domestic or (201) 689-8263 for international access, or join via the company's website.

What are the key programs being developed by Fulcrum Therapeutics?

Fulcrum's lead programs include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.